5 completed, 1 terminated, 1 unknown. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 2.0 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2011-09-01 | 2022-12-12 |
| iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) iSONEP (sonepcizumab/LT1009) - Pigment Epithelial Detachment | Phase 1 | Terminated | Lpath, Inc. | 12 | 2011-03-01 | 2013-04-23 |
| Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy ranibizumab 2.0mg - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Unknown | Retina Consultants of Hawaii | 20 | 2010-11-01 | 2010-11-25 |
| Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) high-dose ranibizumab, ranibizumab - PCV, Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Hawaii Pacific Health | 24 | 2010-11-01 | 2017-10-09 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) ranibizumab intravitreal injection - Polypoidal Choroidal Vasculopathy | Phase 1 | Completed | Hawaii Pacific Health | 17 | 2007-01-01 | 2014-11-05 |
| Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 0.3 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2006-05-01 | 2019-04-16 |
Choroidal Neovascularization (3) · Myopia, Degenerative (1) · Pseudoxanthoma Elasticum (1) · Retinal Detachment (1) · Retinal Telangiectasis (1) · Vascular Diseases (1) · Vitelliform Macular Dystrophy (1) · von Hippel-Lindau Disease (1)
Choroid Diseases (7) · Eye Diseases (7) · Metaplasia (7) · Neovascularization, Pathologic (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Uveal Diseases (7) · Choroidal Neovascularization (4) · Cardiovascular Diseases (2) · Retinal Diseases (2) · Abnormalities, Multiple (1) · Angiomatosis (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Ranibizumab (6) · sonepcizumab (1)
Hawaii Pacific Health (2) · Southeast Retina Center, Georgia (2) · Lpath, Inc. (1) · Manhattan Eye, Ear & Throat Hospital (1) · Retina Consultants of Hawaii (1)
United States (7)
Dennis M. Marcus, M.D. (2) · Gregg T Kokame, MD, MMM (2) · Glenn Stoller, MD (1) · Gregg T Kokame, MD (1) · Lawrence A. Yannuzzi, MD (1)